Pedersen-Bjergaard J, Philip P
Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
Cancer Genet Cytogenet. 1991 Aug;55(1):119-24. doi: 10.1016/0165-4608(91)90246-q.
Two different classes of therapy-related acute myeloid leukemia (t-AML) seem to emerge. One class follows therapy with alkylating agents, increases in frequency with age, often presents with myelodysplasia (MDS), responds poorly to chemotherapy, and shows monosomy 7(-7), monosomy 5(-5), or loss of various parts of the long arms of these chromosomes (5q- and 7q-). The other class is related to therapy with cytostatic drugs targeting at DNA-topoisomerase II, often presents with overt leukemia, responds more favorably to chemotherapy, and shows balanced chromosome aberrations, primarily translocations involving chromosome bands 11q23 and 21q22. These two classes of t-AML may have their counterparts in de-novo acute myeloid leukemia (de-novo AML).
似乎出现了两种不同类型的治疗相关急性髓系白血病（t-AML）。一类是在接受烷化剂治疗后发生的，其发病率随年龄增长而增加，常伴有骨髓增生异常（MDS），对化疗反应较差，表现为7号染色体单体（-7）、5号染色体单体（-5）或这些染色体长臂各部分的缺失（5q-和7q-）。另一类与靶向DNA拓扑异构酶II的细胞毒性药物治疗有关，常表现为明显的白血病，对化疗反应较好，表现为染色体平衡畸变，主要是涉及11q23和21q22染色体带的易位。这两类t-AML在原发性急性髓系白血病（原发性AML）中可能有其对应类型。
